The progression of chronic renal failure (CRF) levels.2,6 In the MRFIT study, the risk of developing ESRD increased exponentially with increasing levels remains one of the main challenges in clinical nephrology. Over the last quarter of a century, animal of blood pressure.4 Patients with underlying chronic renal disease are also at increased risk from hyperexperimentation has identified many of the pathophysiological mechanisms underlying the associated tensive-induced renal damage. This is likely to be due to the susceptibility of their glomeruli to systemic renal scarring process. Consequently, research has implicated a wide range of mediators, including hypertension, as remnant glomeruli are poorly autoregulated and therefore allow the unopposed transprominent roles for cytokines, chemokines and growth factors.1 This has suggested therapies based mission of systemic hypertension to their capillary bed. 7 The ensuing glomerular capillary hypertension on the manipulation of these mediators and aimed at the prevention of progressive renal fibrosis and funcaccelerates the development of glomerulosclerosis.7
Having established that systemic hypertension tional decline.1 Unfortunately, the relevance of these interventions and their applicability to patients with accelerates the progression of CRF, experimental and clinical evidence has confirmed the beneficial effect progressive renal insufficiency remain uncertain. Meanwhile, nephrologists continue to be faced with of its control on the progression of diabetic and nondiabetic nephropathies.8 However, questions have an increasing number of patients with progressive CRF. It is therefore imperative to review available been asked as to target blood pressure and the type of antihypertensive agents used. Before we examine clinical interventions based on the manipulation of known clinical risk factors for the progression of CRF.
the arguments for different target blood pressures and preferential use of some antihypertensive agents, we Hypertension has been linked to the progression of chronic renal failure (CRF) since the pioneering days shall examine briefly the role of other risk factors affecting the progression of CRF that may interact of Richard Bright in the 19th century and Volhard and Farr early this century. More recently, a large with hypertension and influence its management. It has been known for many years that proteinuria body of evidence has suggested that the progression of CRF is accelerated by raised systemic blood presis a good predictor of progressive CRF.9 The North Italian Cooperative Study Group has recently consure.2,3 The Multiple Risk Factor Intervention Trial (MRFIT) identified systemic hypertension as a significfirmed the importance of proteinuria as a poor prognostic factor in patients with CRF.3 In this study, the ant risk factor for the development of endstage renal disease (ESRD).4 This study also confirmed the rate of decline of renal function was proportional to the severity of proteinuria, with patients with heavy increased susceptibility of hypertensive Black patients to progressive renal failure. 4 The Modification of Diet proteinuria (>3 g/24 h) having the worst prognosis. Recently, an increasing body of experimental data in Renal Disease (MDRD) study showed that the progression of CRF was linked to the level of systemic has suggested that proteinuria may be nephrotoxic, thus contributing to the progression of renal disease.10 blood pressure with Black as well as proteinuric patients both at increased risk.5 More recently, the The transudation of protein and proteinaceous material through glomeruli with a raised capillary presNorth Italian Cooperative Study Group identified a mean arterial blood pressure (MAP) value of sure is likely to cause glomerular cells to proliferate and increase their synthesis of extracellular matrix 107 mmHg (around 140/90 mmHg) as discriminatory, with patients with higher values having an accel-(ECM) components.10 Similarly, the increased filtration of proteins and their reabsorption by proximal erated loss of renal function over a 30-month followup period.3 Others have identified a diastolic blood tubular cells has been shown to stimulate the proliferation of these cells, and their release of chemokines pressure value of 85-90 mmHg, with patients with higher values having a rate of progression almost and cytokines as well as their synthesis of ECM.10 With that in mind, proteinuria is becoming to be seen twice as fast as those with lower blood pressure as an important consequence of systemic and glomerperfusion through an endothelin-mediated vasoconstriction. 23 Smoking is also known to worsen ular hypertension that may be contributing directly to both glomerulosclerosis and tubulointerstitial fibrosis.
hyperlipidaemia. These observations may explain the recent finding that cigarette consumption affects the The reduction of proteinuria should therefore be an important goal of antihypertensive therapy. It is also rate of decline of CRF in a dose-dependent fashion, with the risk of ESRD in those smoking in excess of a good predictor of the long-term success of antihypertensive treatment of progressive CRF.11
15 packs-year increased 5.8-fold. 24 Of interest, in this study the odds ratio for ESRD in smokers was even Hyperlipidaemia has been linked to the progression of CRF for many years.12 Experimental evidence higher in those not treated with an angiotensinconverting-enzyme inhibitor (ACEI), reaching 10.1-has confirmed an association, as exposure of glomerular and tubular cells to low-density lipoprotein (LDL) fold compared to those treated with an ACEI, who had an odds ratio of 1.4.24 With these observations in and its oxidized variant (oxLDL) stimulates their proliferation, induce injury and apoptosis, and stimulates mind, antihypertensive strategies should include a reduction or stoppage of smoking. their ECM production, thus contributing to fibrosis. 13 The reduction of hyperlipidaemia through dietary or
The first question I would like to address is what should be the target blood pressure to slow or halt pharmacological manipulations prevents progressive experimental CRF. In patients with CRF, an associthe progression of CRF? Data from the MRFIT25 and the MDRD26,27 have identified African-Americans ation has been described linking raised serum cholesterol and triglycerides levels and the progression of and proteinuric patients at increased hypertensive risk. This led to the suggestion that these patients diabetic and non-diabetic nephropathies. More specifically, raised circulating levels of LDL and apoproshould achieve lower blood pressure levels in order to reach a similar level of protection against progresstein B correlate closely with the rate of decline of CRF, particularly the levels of complex triglycerideive CRF. 27 In diabetic patients, preliminary data suggest that the level of as these agents have been shown to inhibit mesangial proliferation and ECM production. 17 Antihypertensive blood pressure control may also be a function of the quality of glycaemia control; patients with poor glystrategies may have in the future to be lipid-friendly, avoiding worsening of hyperlipidaemia and prefercaemia control (glycosylated haemoglobin levels/ HbA 1c >9.2%) having a faster rate of decline of renal ably reducing circulating lipids levels.
Over the last decades, more attention has been function compared to those with a better metabolic control for an equal degree of blood pressure conpaid to the potential nephrotoxicity of cigarette smoking. The Multiple Risk Factor Intervention Trial trol.28 With good metabolic control (HbA 1c <9.2%), MAP of approximately 95 mmHg led to the normal-(MRFIT) has identified smoking as an independent risk factor for the development of end-stage renal ization of the rate of decline in glomerular filtration rate (1-1.5 ml/min/year).28 In these type I diabetic disease (ESRD).18 Smoking can exacerbate systemic hypertension. Smoking as little as a single cigarette is patients, the effect of blood pressure and metabolic control on progression was independent of the type associated with a rise in systemic blood pressure. 19 In essential hypertension, the prevalence of microalbuof antihypertensive agent used (ACEI or non-ACEI). These observations highlight the interdependence of minuria is almost double in smokers,20 while in diabetic patients the risk of microalbuminuria is 2.8 risk factors in the control of progressive CRF. Whether other metabolic risk factors, such as hyperlipidaemia, greater in smokers. 21 In insulin-dependent diabetes mellitus (IDDM) patients, smoking also accelerates have also to be taken into consideration in relation to blood pressure control is currently unknown. the progression from microalbuminuria to overt proteinuria. Tobacco smoking has been shown to have
The second question centres around the type of antihypertensive agent used. A large and growing direct renal haemodynamic effects leading to glomerular hyperfiltration which may explain the detribody of evidence favours ACE inhibitors.29 They control systemic as well as glomerular hypertensions and mental effect of smoking on proteinuria. 22 Others have suggested that smoking could reduce renal reduce proteinuria; in other words, the perfect profile for slowing the progression of CRF. Large clinical CRF, and the beneficial effect of such restriction on blood pressure control.40 Patients should stop smoktrials in diabetic30 and non-diabetic31,32 nephropathies seem to confirm this impression. As mentioned ing, as this is likely to reduce proteinuria, facilitate blood pressure control and ultimately slow progresabove, these agents may also have a therapeutic advantage in hypertensive smokers. On the other sion. Lipids should be monitored, in particular LDL and apoprotein B levels and corrected with an HMG hand, they may be less effective when compared to other agents in Black patients. In diabetic and nonCoA reductase inhibitor in view of the presence of associated hypertension and renal disease. We diabetic progressive nephropathies, ACEIs may prove more effective than other drugs in heavy proteinuric should avoid antihypertensive agents that may exacerbate hyperlipidaemia. All antihypertensive patients (>5 g/24 h) and at higher levels of blood pressure control (MAP between 100 and agents are not created equal and neither are the patients who suffer from CRF. 102 mmHg).8 If lower levels of blood pressure control (MAP around 92 mmHg) are reached through other A.M. El-Nahas Sheffield Kidney Institute antihypertensive agents, the beneficial advantage of ACE inhibitors may be reduced.8 Emerging data in
Northern General Hospital N. Tamimi NIDDM suggest that non-dihydropyridine calcium channel blockers (NDCCB) such as diltiazem33 and
Renal Unit Kent and Canterbury Hospital verapamil34 are equally effective in reducing overt proteinuria. Diltiazem, unlike nifedipine, seems to have a similar effect on glomerular size permselectivity to ACE inhibitors.35 Diltiazem also appears to be we should be aiming for MAP levels around 
